Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

Four patients experienced alleviation of symptoms and reduced their daily prednisone dosages; one of them also discontinued cyclosporine A and two of them also discontinued belimumab. The other 5 ...

Panelists discuss the differences in efficacy and safety profiles between belimumab and voclosporin for lupus nephritis (LN) and how payers are evaluating their value, including considerations of cost ...

While GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have been important advances in the treatment arsenal for lupus nephritis (LN), a serious complication of systemic lupus ...

Neuropsychiatric systemic lupus erythematosus (NPSLE), or central nervous system lupus, can be challenging to diagnose ...

We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people. For the first time, NICE ...

B-cell–directed therapy has attracted much attention because of its unique mechanism of action. Belimumab and obinutuzumab, as representative drugs for B-cell–directed therapy, have shown their ...

Belimumab added to standard of care induction therapy improved control of disease activity and led to a reduction in glucocorticoid dosages in real-world patients with proliferative lupus nephritis.

Novel biologics for lupus nephritis, including obinutuzumab, abatacept, and belimumab, show efficacy within certain time frames. Among the novel biological agents for lupus nephritis, renal response ...

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants ...